World Companion Diagnostics and Liquid Biopsy Summit APAC

Memo

Precision healthcare in the Asia-Pacific region has seen a surge in advancements within the last 12 months; including NGS and laboratory-based tests, approvals (like a companion diagnostic test for lung cancer), and evolving regulations. The World Companion Diagnostics and Liquid Biopsy Summit APAC provides an opportunity to unite with your fellow biopharma, diagnostic providers and leading academics to navigate liquid biopsy and companion diagnostic testing and ensure precision therapies become accessible to all patients. Join 100+ of your colleagues working within Precision Medicine, Companion Diagnostics, Medical Affairs and Commercialization from China, Japan, Australia, Singapore and more to accelerate the co-development of drug-CDx combinations and liquid biopsy testing to deliver life changing therapies to patients. URLs:Tickets: https://go.evvnt.com/2609770-2?pid=5569Brochure: https://go.evvnt.com/2609770-3?pid=5569Date and Time: On Wednesday November 13, 2024 at 7:30 am to Thursday November 14, 2024 at 5:15 pmVenue details: Conrad Centennial Singapore, 2 Temasek Boulevard, Singapore, 038982, SingaporePrices:Service and Solution Provider - Conference Only: USD 3299.00,Drug Developers and Researchers - Conference Only: USD 0.50Speakers: Xiaofang Zhuo, Global Regulatory Affairs Director, Diagnostic and Digital Health, Johnson and Johnson, Zhirong Shen, Vice president, BeiGene, Junpei Soeda, Head Japan Medical Affairs, Takeda Pharmaceutical, Tsuyoshi Morishita, Associate Director, Global Biomarker, Kyowa Kirin, Mike Ye, Head-CDx and Biomarker, CStone Pharmaceuticals, Sharon Liang, Executive Director, Head, Precision Medicine and Digital Health, Bristol Myers Squibb, Donna Li, Senior CDx Regulatory Affairs Manager, Daiichi Sankyo, Ian Black, Chief Executive Officer, Omico, Xin Ye, Director, Oncology Precision Medicine and Diagnostics, Johnson and Johnson, Chunming Ding, Associate Director, Department of Pathology, Fudan University Shanghai Cancer Center, Lei Tang, Head of China Translation Medicine Early Development, Sanofi, Li Feng, Director of Translational Development, Harbour BioMed, Michelle Yang, Director, Head of PMO, OBI Pharma, Min Qing, Director, Oncology Precision Medicine and Diagnostics, Johnson and Johnson, Matthew Nelson, Vice President Biopharma Partnerships, Foundation Medicine, Tammer Farid, Vice President and Head of Genomics Access, Illumina, Qinmei Ji, Associate Director, Precision Medicine Team Lead in China, Daiichi Sankyo, Colton Ballou, Associate Director, Business Development, Foundation Medicine, Michael David Winther, Senior Director, Engine Biosciences